biostudies-literatureMark DBNHLBI NIH HHS94-102https://www.ebi.ac.uk/biostudies/studies/S-EPMC5046832biostudies-literatureUnknown165(2)<h4>Background</h4>PROMISE (PROspective Multicenter Imaging Study for Evaluation of Chest Pain) found that initial use of at least 64-slice multidetector computed tomography angiography (CTA) versus functional diagnostic testing strategies did not improve clinical outcomes in stable symptomatic patients with suspected coronary artery disease (CAD) requiring noninvasive testing.<h4>Objective</h4>To conduct an economic analysis for PROMISE (a major secondary aim of the study).<h4>Design</h4>Prospective economic study from the U.S. perspective. Comparisons were made according to the intention-to-treat principle, and CIs were calculated using bootstrap methods. (ClinicalTrials.gov: NCT01174550).<h4>Setting</h4>190 U.S. centers.<h4>Patients</h4>9649 U.S. patients enrolled in PROMISE between July 2010 and September 2013. Median follow-up was 25 months.<h4>Measurements</h4>Technical costs of the initial (outpatient) testing strategy were estimated from Premier Research Database data. Hospital-based costs were estimated using hospital bills and Medicare cost-charge ratios. Physician fees were taken from the Medicare Physician Fee Schedule. Costs were expressed in 2014 U.S. dollars, discounted at 3% annually, and estimated out to 3 years using inverse probability weighting methods.<h4>Results</h4>The mean initial testing costs were $174 for exercise electrocardiography; $404 for CTA; $501 to $514 for pharmacologic and exercise stress echocardiography, respectively; and $946 to $1132 for exercise and pharmacologic stress nuclear testing, respectively. Mean costs at 90 days were $2494 for the CTA strategy versus $2240 for the functional strategy (mean difference, $254 [95% CI, -$634 to $906]). The difference was associated with more revascularizations and catheterizations (4.25 per 100 patients) with CTA use. After 90 days, the mean cost difference between the groups out to 3 years remained small.<h4>Limitation</h4>Cost weights for test strategies were obtained from sources outside PROMISE.<h4>Conclusion</h4>Computed tomography angiography and functional diagnostic testing strategies in patients with suspected CAD have similar costs through 3 years of follow-up.<h4>Primary funding source</h4>National Heart, Lung, and Blood Institute.Annals of internal medicineEconomic Outcomes With Anatomical Versus Functional Diagnostic Testing for Coronary Artery Disease.PMC5046832R01 HL098237R01 HL098305R01 HL098236R01 HL098235Hoffmann UAnstrom KJKnight JDMark DBCowper PACooper LSDaniels MRPROMISE InvestigatorsDouglas PSPatel MRLee KLFederspiel JJDavidson-Ray LfalseEconomic Outcomes With Anatomical Versus Functional Diagnostic Testing for Coronary Artery Disease.<h4>Background</h4>PROMISE (PROspective Multicenter Imaging Study for Evaluation of Chest Pain) found that initial use of at least 64-slice multidetector computed tomography angiography (CTA) versus functional diagnostic testing strategies did not improve clinical outcomes in stable symptomatic patients with suspected coronary artery disease (CAD) requiring noninvasive testing.<h4>Objective</h4>To conduct an economic analysis for PROMISE (a major secondary aim of the study).<h4>Design</h4>Prospective economic study from the U.S. perspective. Comparisons were made according to the intention-to-treat principle, and CIs were calculated using bootstrap methods. (ClinicalTrials.gov: NCT01174550).<h4>Setting</h4>190 U.S. centers.<h4>Patients</h4>9649 U.S. patients enrolled in PROMISE between July 2010 and September 2013. Median follow-up was 25 months.<h4>Measurements</h4>Technical costs of the initial (outpatient) testing strategy were estimated from Premier Research Database data. Hospital-based costs were estimated using hospital bills and Medicare cost-charge ratios. Physician fees were taken from the Medicare Physician Fee Schedule. Costs were expressed in 2014 U.S. dollars, discounted at 3% annually, and estimated out to 3 years using inverse probability weighting methods.<h4>Results</h4>The mean initial testing costs were $174 for exercise electrocardiography; $404 for CTA; $501 to $514 for pharmacologic and exercise stress echocardiography, respectively; and $946 to $1132 for exercise and pharmacologic stress nuclear testing, respectively. Mean costs at 90 days were $2494 for the CTA strategy versus $2240 for the functional strategy (mean difference, $254 [95% CI, -$634 to $906]). The difference was associated with more revascularizations and catheterizations (4.25 per 100 patients) with CTA use. After 90 days, the mean cost difference between the groups out to 3 years remained small.<h4>Limitation</h4>Cost weights for test strategies were obtained from sources outside PROMISE.<h4>Conclusion</h4>Computed tomography angiography and functional diagnostic testing strategies in patients with suspected CAD have similar costs through 3 years of follow-up.<h4>Primary funding source</h4>National Heart, Lung, and Blood Institute.2016-01-01T00:00:00Z2016 Jul2026-04-30T18:24:10.552Z2019-03-27T02:25:41ZS-EPMC50468322721459710.7326/m15-263910.7326/M15-2639